Holen Sie sich die Stockscreener-App
1.13
1.80%
0.02
Handel nachbörslich:
1.13
Acumen Pharmaceuticals Inc Aktie (ABOS) Neueste Nachrichten
Acumen Pharmaceuticals (NASDAQ:ABOS) Now Covered by Citigroup - Defense World
Citi initiates Acumen Pharmaceuticals stock with buy rating By Investing.com - Investing.com South Africa
Citigroup Initiates Coverage on Acumen Pharmaceuticals (ABOS) wi - GuruFocus
Bank of America Corp DE Boosts Holdings in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Cantor Fitzgerald Estimates ABOS FY2026 Earnings - Defense World
Pre-market Movers: EVGN, WINT, CARM, UNCY... - RTTNews
Two Sigma Investments LP Lowers Holdings in Vicor Co. (NASDAQ:VICR) - Defense World
Two Sigma Investments LP Sells 8,239 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Acumen Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Deutsche Bank AG Increases Holdings in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Millennium Management LLC Acquires New Holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
Millennium Management LLC Cuts Stock Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Cryptocurrency Stocks To Follow Today – May 30th - Defense World
Halozyme to Participate at Upcoming Investor Conferences - The Malaysian Reserve
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications - Quantisnow
FY2025 EPS Estimates for ABOS Reduced by Cantor Fitzgerald - Defense World
Dimensional Fund Advisors LP Purchases 41,460 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Acumen targets ALTITUDE-AD Phase 2 topline results in late 2026 while advancing subcutaneous Sabirnetug development - MSN
Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT) and Ovid Therapeutics (OVID) - The Globe and Mail
Acumen Pharmaceuticals’ Earnings Call Highlights Progress in Alzheimer’s Treatment - TipRanks
Tower Research Capital LLC TRC Purchases 16,714 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Transcript : Acumen Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 08 - marketscreener.com
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q1 2025 Earnings Call Transcript - Insider Monkey
Barclays PLC Raises Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Barclays PLC Raises Stock Holdings in Babcock & Wilcox Enterprises, Inc. (NYSE:BW) - Defense World
Acumen Pharmaceuticals Q1 2025 Financial Update - TipRanks
ABOS Reports Decline in Cash Reserves to Support Operations | AB - GuruFocus
Earnings call transcript: Acumen Pharmaceuticals Q1 2025 financial results and stock gains - Investing.com Nigeria
Acumen (ABOS) Advances in Alzheimer's Treatment Study | ABOS Sto - GuruFocus
ACUMEN PHARMACEUTICALS Earnings Results: $ABOS Reports Quarterly Earnings - Nasdaq
Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights - The Manila Times
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Acumen Pharmaceuticals (ABOS) to Release Earnings on Tuesday - Defense World
Acumen Pharmaceuticals Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView
Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference - The Manila Times
Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 - The Manila Times
Upcoming Earnings: Alzheimer's Drug Developer Acumen Pharmaceuticals Reports Q1 Results May 13 - Stock Titan
Halozyme to Participate in the BofA Securities 2025 Healthcare Conference - The Malaysian Reserve
Renaissance Technologies LLC Cuts Stake in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Halozyme to Report First Quarter 2025 Financial and Operating Results - Yahoo Finance
JPMorgan Chase & Co. Has $1.61 Million Stock Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
ABOS stock touches 52-week low at $0.89 amid market challenges By Investing.com - Investing.com South Africa
ABOS stock touches 52-week low at $0.89 amid market challenges - Investing.com Australia
European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer - Finansavisen
Financial Review: Acumen Pharmaceuticals (NASDAQ:ABOS) & Precision BioSciences (NASDAQ:DTIL) - The AM Reporter
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting - The Manila Times
Game-Changing Trial Screening Method: Acumen Advances Alzheimer's Research with pTau217 Innovation - Stock Titan
Charles Schwab Investment Management Inc. Acquires 18,004 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors - The Manila Times
What is HC Wainwright’s Forecast for ABOS FY2029 Earnings? - Defense World
FY2029 Earnings Forecast for ABOS Issued By HC Wainwright - The AM Reporter
UBS Group Lowers Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target to $4.00 - Defense World
Acumen Pharmaceuticals outlines ALTITUDE AD Phase 2 plans and late 2026 data timeline - MSN
HC Wainwright Has Lowered Expectations for Acumen Pharmaceuticals (NASDAQ:ABOS) Stock Price - Defense World
Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Cut to $11.00 by Analysts at HC Wainwright - The AM Reporter
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):